Joint Formulary & PAD

Dapoxetine hydrochloride - Premature Ejaculation

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Tablets
Associated Icons :
NFD1
SPC
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Dapoxetine hydrochloride
Indication :
Premature Ejaculation
Group Name :
Keywords :
Brand Names Include :
Priligy
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Committee Recommendations (2)

The Surrey Priorities Committee has considered the PCN evidence review and the NICE ESNM40 (Evidence Summary: New Medicine), regarding dapoxetine for the treatment of premature ejaculation:

The commissioning of dapoxetine for premature ejaculation is considered LOW PRIORITY and it is not recommended for routine prescribing.

Dapoxetine should therefore have a BLACK status on the Surrey traffic light system.
INTERIM STATEMENT: The PCN did not reach a consensus following discussions and requested that this topic is referred to the Surrey Priorities Committee for consideration. Please note that Dapoxetine is not on formulary at any of the local acute trusts and therefore GPs should not currently be receiving requests to prescribe.

Other Indications

Below are listed other indications that Dapoxetine hydrochloride is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Premature Ejaculation.